Wachtell, Lipton, Rosen & Katz served as legal advisor to AbbVie, while Ropes & Gray served as legal advisor to ImmunoGen. AbbVie Inc. (NYSE: ABBV) and...
You must be a Standard 1 Year member to access this content.
Ropes & Gray represented ImmunoGen in the deal. ImmunoGen, Inc. (Nasdaq: IMGN) announced it has entered into an exclusive collaboration with Takeda Pharmaceutical Company Limited (TSE:...
You must be a Standard 1 Year member to access this content.
Ropes & Gray represented ImmunoGen in the deal. ImmunoGen, Inc. announced a multi-target license and option agreement to research novel, first-in-class ADCs with ImmunoBiochem Corporation on the...
You must be a Standard 1 Year member to access this content.
Ropes & Gray advised ImmunoGen, while Walder Wyss advised the funds managed by Pharmakon Advisors. ImmunoGen, Inc. (Nasdaq: IMGN) announced it has entered into a term loan...
You must be a Standard 1 Year member to access this content.
Ropes & Gray represented ImmunoGen, Inc. on the deal. ImmunoGen, Inc., a leader in the field of antibody-drug conjugates, announced a global, multi-target license and option agreement...
You must be a Standard 1 Year member to access this content.
Ropes & Gray advised ImmunoGen on the deal. ImmunoGen, a leader in the field of antibody-drug conjugates for cancer treatment, in a clinical collaboration with Gilead...
You must be a Standard 1 Year member to access this content.
Ropes & Gray advised ImmunoGen on the deal. ImmunoGen, a leader in the field of antibody-drug conjugates for cancer treatment, announced a research collaboration with Biosion USA,...
You must be a Standard 1 Year member to access this content.
Ropes & Gray advised ImmunoGen on the deal. ImmunoGen, a leader in the field of antibody-drug conjugates for the treatment of cancer, announced a global, multi-year...
You must be a Standard 1 Year member to access this content.
